匹苯齐莫尔治疗胰腺癌的II期研究。一项西南肿瘤协作组的研究。
Phase II study of pibenzimol in pancreatic cancer. A Southwest Oncology Group study.
作者信息
Kraut E H, Fleming T, Segal M, Neidhart J A, Behrens B C, MacDonald J
机构信息
Ohio State University Health Center, Columbus.
出版信息
Invest New Drugs. 1991 Feb;9(1):95-6. doi: 10.1007/BF00194556.
PMID:1709154
Abstract
Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma.
摘要
23例晚期胰腺腺癌患者接受了匹苯齐莫尔治疗，采用每日静脉给药方案，持续5天。未观察到客观缓解。主要毒性为胰腺毒性，11例患者出现3级高血糖。匹苯齐莫尔对晚期胰腺腺癌患者无效。
Zotero 插件